Last reviewed · How we verify
RL-007
At a glance
| Generic name | RL-007 |
|---|---|
| Sponsor | Recognify Life Sciences |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS) (PHASE2)
- Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RL-007 CI brief — competitive landscape report
- RL-007 updates RSS · CI watch RSS
- Recognify Life Sciences portfolio CI